Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients (SVOSA)

J

Jinling Hospital, China

Status and phase

Active, not recruiting
Phase 3

Conditions

Gastric Cancer
Stomach Neoplasms

Treatments

Drug: S-1
Drug: oxaliplatin
Drug: etoposide
Drug: pharmorubicin

Study type

Interventional

Funder types

Other

Identifiers

NCT02338518
20140621
08Z28 (Other Grant/Funding Number)

Details and patient eligibility

About

Chemotherapy is an important therapeutic method for patients with advanced gastric cancer. However, there is currently no established standard chemotherapeutic regimen in the preoperative or neoadjuvant treatment setting. The aim of our study was to compare the efficacy and toxicity between SEEOX and SOX regimens. The investigators estimate that combined intravenous and intra-arterial intensified SEEOX preoperative chemotherapy may be a safe and promising regimen for locally advanced or initially unresectable gastric cancer patients.

Full description

Gastric cancer patients who will receive neoadjuvant chemotherapy would be included in this study. They would receive combined intravenous and intra-arterial intensified SEEOX neoadjuvant chemotherapy or SOX regimen at random. The efficacy and toxicity of these two regimens would be compared.

Enrollment

297 patients

Sex

All

Ages

30 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Eastern Cooperative Oncology Group(ECOG) score 0-2
  • Ambulatory males or females, aged 30-70 years.
  • Unresectable gastric cancer (Tumors with bulky nodal metastases surrounding the celiac artery and its branches or invasion of adjacent structures such as pancreas, omentum, esophagus, and aorta were considered unresectable)
  • Life expectancy more than 3 months
  • Give written informed consent, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.
  • Normal hepatic, renal, and bone marrow function (GPT<2 fold of upper limit value; white blood cell count>4000/dl, Tbil<1.5mg/dl, Cr<1.5 fold of upper limit value)

Exclusion criteria

  • Patients can not bear surgical procedure.
  • Pregnant or lactating women.
  • Previous cytotoxic chemotherapy, radiotherapy or immunotherapy.
  • History of another malignancy within the last five years.
  • History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the Investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake.
  • Clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery disease, New York Heart Association (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication or myocardial infarction within the last 12 months.
  • Organ allografts requiring immunosuppressive therapy.
  • Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease.
  • Moderate or severe renal impairment: serum creatinine > 1.5 x upper limit of normal (ULN).
  • Hypersensitivity to any drug of the study regimen.
  • With abdominal cavity implantation metastasis or distant metastasis.
  • Unwilling or unable to comply with the protocol for the duration of the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

297 participants in 2 patient groups

SEEOX group
Experimental group
Description:
A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, oxaliplatin 100 mg/m2, etoposide 80 mg/m2, and pharmorubicin 30 mg/m2 were administered from the celiac artery on day 1. 80~120 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
Treatment:
Drug: pharmorubicin
Drug: etoposide
Drug: oxaliplatin
Drug: S-1
SOX group
Active Comparator group
Description:
A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, patients received intravenous oxaliplatin 130 mg/m2 on day 1, and 80~120 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
Treatment:
Drug: oxaliplatin
Drug: S-1

Trial contacts and locations

0

Loading...

Central trial contact

Qi He, M.D., PhD.; Xunlin Wang, M.D., PhD.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems